If you’ve started or continued opioid use disorder treatment through a phone or video visit anytime since 2020, you’ve been relying on a rule the federal government still hasn’t gotten around to finalizing. Not because it failed. Because for six years running, the DEA has kept punting the real decision down the road.
The One Piece That Did Get Settled
There’s a genuine exception worth knowing about, since it’s actual good news buried inside a messier story. Buprenorphine specifically got its own permanent rule back in January 2025, letting a doctor start someone on it through telehealth without requiring an in-person visit first. That part isn’t temporary anymore. If telehealth aftercare for buprenorphine is part of how you or someone you love stays connected to treatment, that pathway is on solid legal ground.
Everything Else Is Still Year-to-Year
The broader rule, covering telehealth prescribing of other controlled substances used in addiction and mental health treatment, hasn’t gone the same way. Since the pandemic-era flexibilities were first put in place in 2020, the DEA has extended them four separate times rather than making a permanent decision. The current extension runs through the end of 2026. A real, permanent framework, something called Special Registration, has been proposed and re-proposed for years and still hasn’t been finalized. The DEA’s own timeline now points to November 2026 for a possible final rule, and that date has already slipped more than once.
Why This Keeps Getting Delayed
Part of it is genuine disagreement. DEA and HHS have reportedly been at odds over how much oversight telehealth prescribing of controlled substances needs, balancing real concerns about diversion and misuse against the access problems that come from forcing someone into an in-person visit they may not be able to get to. Rural patients and people without reliable transportation are the ones with the most to lose if this lapses without a replacement. Nobody in this fight seems to want patients to lose access entirely, which is probably why the DEA keeps extending rather than letting it expire, but a six-year pattern of temporary fixes isn’t exactly reassuring either.
The Flexibilities Are Still Active Today
Here’s the practical reality. As of today, the flexibilities are in effect and extended through the end of 2026. Nothing is lapsing tomorrow. But a program or provider relying entirely on telehealth prescribing for controlled substances beyond buprenorphine is operating on a rule that could, in theory, not get renewed a fifth time. Most people in this field expect another extension if the permanent rule still isn’t ready, since an abrupt cutoff would cause real harm, but “most people expect” isn’t the same thing as a guarantee written into law.
Where This Leaves Families in Bay County
If telehealth is part of your treatment plan or your aftercare, it’s worth asking your provider directly which category your prescriptions fall under, the already-permanent buprenorphine pathway or the still-temporary broader one. Florida Springs Wellness and Recovery Center is in Panama City, and our own telehealth aftercare options are built with this uncertainty in mind, not just handed to someone and left unexplained. You shouldn’t have to track federal rulemaking timelines yourself just to know whether your treatment is stable. That’s on us to keep track of, not you.
